Teva Pharmaceutical Industries CEO Kåre Schultz's 2018 pay jumps 91% to $32M

Teva Pharmaceutical Industries reports 2018 executive compensation

By ExecPay News

Published: April 16, 2019

Teva Pharmaceutical Industries reported fiscal year 2018 executive compensation information on April 16, 2019.

In 2018, five executives at Teva Pharmaceutical Industries received on average a compensation package of $11M, a 115% increase compared to previous year.

Average pay of disclosed executives at Teva Pharmaceutical Industries

Kåre Schultz, Chief Executive Officer, received $32M in total, which increased by 91% compared to 2017. 62% of Schultz's compensation, or $20M, was in bonus. Schultz also received $3.8M in non-equity incentive plan, $1.5M in option awards, $2M in salary, $4.5M in stock awards, as well as $680K in other compensation.

Carlo de Notaristefani, Executive Vice President, Global Operations, received a compensation package of $7.2M, which increased by 62% compared to previous year. 49% of the compensation package, or $3.5M, was in stock awards.

Hafrun Fridriksdottir, Executive Vice President, Global Research and Development, earned $6M in 2018, a 61% increase compared to previous year.

Mark Sabag, Executive Vice President, Global Human Resources, received $5.2M in 2018, which increases by 108% compared to 2017.

Michael McClellan, Chief Financial Officer, earned $4.9M in 2018, a 353% increase compared to previous year.